Thyrocare for 70%+ gains after correction
Date: 3 Nov’24
Symbol: THYROCARE
Timeframe: Daily
Apparently, Thyrocare seems to be in Wave III which could conclude around 1000. Post which Wave IV correction could come down to 840-820 levels marked as Demand Zone in the chart. And Wave V then will be heading to 1430 to 1500 levels (70%+ from 830 levels) depending on where Wave IV ends. Its all time high price is 1465.
This is not a trade recommendation. Please do your own analysis.
HINGLISH VERSION
Jaahir taur par, Thyrocare Wave III mein lagta hai jo 1000 ke aaspaas samaapt ho sakta hai. Jiske baad Wave IV chart mein Demand Zone ke roop mein ankit 840-820 ke star tak neeche aa sakta hai. Aur Wave V tab 1430 se 1500 ke star (830 ke star se 70%+) ki taraf badh jaega, yah is baat par nirbhar karega ki Wave IV kahaan samaapt hota hai. Thyrocare ki all time high keemat 1465 hai.
Yah koi trade lene ki salah nahin hai. Kripya apana vishleshan khud karein.
Symbol: THYROCARE
Timeframe: Daily
Apparently, Thyrocare seems to be in Wave III which could conclude around 1000. Post which Wave IV correction could come down to 840-820 levels marked as Demand Zone in the chart. And Wave V then will be heading to 1430 to 1500 levels (70%+ from 830 levels) depending on where Wave IV ends. Its all time high price is 1465.
This is not a trade recommendation. Please do your own analysis.
HINGLISH VERSION
Jaahir taur par, Thyrocare Wave III mein lagta hai jo 1000 ke aaspaas samaapt ho sakta hai. Jiske baad Wave IV chart mein Demand Zone ke roop mein ankit 840-820 ke star tak neeche aa sakta hai. Aur Wave V tab 1430 se 1500 ke star (830 ke star se 70%+) ki taraf badh jaega, yah is baat par nirbhar karega ki Wave IV kahaan samaapt hota hai. Thyrocare ki all time high keemat 1465 hai.
Yah koi trade lene ki salah nahin hai. Kripya apana vishleshan khud karein.
Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.